09/674733

Cof C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: SZARDENINGS=1

In re Patent of:	)	Conf. No.: 3759
SZARDENINGS et al.	)	
Patent No.: 7,008,925	)	Washington, D.C.
Issued: March 7, 2006	)	April 20, 2007
For: MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS	)	ATTN: Certificate of Correction Division

REQUEST FOR EXPEDITED CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Post Issue
401 Dulany Street
Alexandria, VA 22314

Sir:

In checking over the printed copy of the above-identified patent, we have found the following error that is the fault of the Patent and Trademark Office. It is respectfully requested that this error be corrected in accordance with 37 CFR §1.322(a). The error to be corrected is listed below.

The PTO erred by publishing, as the sequence listing for this case (cols. 39-46), a sequence listing associated with some other case. This is evident from comparison of cols. 39-46 with the 8 page sequence listing filed June 12, 2001.

	Cols. 39-46	June 12, 2001
Number of Sequences	22	15
SEQ ID NO: 1	30 base DNA sequence	13 a.a. Polypeptide sequence
SEQ ID NO: 2	10 base DNA sequence	13 a.a. Polypeptide sequence

and so forth.

It is important that the error be corrected because one or more of SEQ ID NOS: 1-15 are referred to in claims 9 or 10.

We are attaching one copy of the Certificate of Correction form.

In accordance with MPEP §1480.01, in an effort to expedite processing of this request, copies of cols. 39-46 of the patent, and the June 12, 2001, filing are attached, so that the PTO can verify that an error was made. Consequently, correction should be expedited pursuant to MPEP §1480.01.

Granting of this request is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By _____
Iver P. Cooper
Registration No. 28,005

:dtb
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\ipc\n-q\Plou\Szardenings1\2007-04-20CertCor322PTOFault.doc

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete the sequence listing at cols. 39-46 and insert therefor the following sequence listing:

SEQUENCE LISTING

<110> Szardenings, Michael
Muceniece, Ruta
Mutule, Ilze
Mutulis, Felikss
Jarl, Wikberg

<120> Melanocortin 1 Receptor Selective Compounds

<130> 1085.0050000/RWE/ALS

<140> 09/674,733

<141> 1999-05-05

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<150> PCT/GB99/01388
<151> 1999-05-05

<150> SE 9801571-2
<151> 1998-05-05

<160> 15

<170> PatentIn version 3.0

<210> 1
<211> 13
<212> PRT
<213> Artificial

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 1

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (7)..(7)

<223> D amino acid

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

APR 25 2007

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<400> 2

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 3

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 3

Tyr Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 4

<211> 13

<212> PRT

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<213> Artificial
<220>

<223> Synthetic peptide with high affinity for melanocoritn receptor 1

<400> 4

Tyr Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 5

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 5

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val Tyr
1 5 10

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> 6

<211> 12

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 6

Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 7

<211> 13

<212> PRT

<213> Artificial

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 7

Thr Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 8

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 8

Ser Thr Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 9

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 9

Ser Ser Val Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 10

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

7 25 2007

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> 11

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<400> 11

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 12

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> D amino acid

<400> 12

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 13

<211> 13

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> N-Methyl-L-Serine

<400> 13

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 14

<211> 13

<212> PRT

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (13)..(13)

<223> MeVal

<400> 14

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 15

<211> 13

<212> PRT

<213> Artificial

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,008,925
APPLICATION NO.: 09/674,733
ISSUE DATE : March 7, 2006
INVENTOR(S) : SZARDENINGS et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (7)..(7)

<223> N-Methyl-D-Phenylalanine

<400> 15

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

MAILING ADDRESS OF SENDER (Please do not use customer number below):
624 Ninth Street, NW
Suite 300
Washington, DC 20001-5303

Cell Culture

RAW 264.7 cells (TIB-71), obtained from American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md., 20852, USA, and cultured in Dulbecco's modified Eagle medium (Gibco, BRL) supplemented with 10% heat-inactivated fetal bovine serum, 100 IU penicillin/ml and 100 μg streptomycin/ml at 37° C. in a humidified atmosphere of 95% air and 5% CO_2. Cells grown in monolayers were detached from the culture flasks and collected by low speed centrifugation (700×g).

Incubation of Compounds of the Invention with RAW 264.7 Cells

The cells obtained as above were resuspended in F-12 (HAM) medium (Gibco, BRL) and distributed into 96-well plates at a density of 2.5×10^5 cells per well, and incubated with 100 ng/mL bacterial lipopolysaccharide (L4391, Sigma Chemical Company, P.O. Box 14508, St. Louis, Mo. 63178, USA), 5 units/mL of mouse recombinant interferon gamma (15517, Sigma Chemical Company, P.O. Box 14508, St Louis, Mo. 63178, USA) and the compounds of the invention using concentrations ranging 01 μM, for 16 h, whereafter an aliquot of the medium was collected for measurement of nitric oxide (NO).

Measurement of Nitric Oxide

Nitric oxide was measured by monitoring the nitrite production essentially using the method of Wishnok et al. (Methods in Enzymology, 1996, 268, 130–151). In brief 50 μL of culture medium was mixed with 50 μL Griess reagent (i.e. a 1:1 mixture of 0.1% N-naphthylethylenediamine dihydrochloride and 1% sulfanilamide in 5% (v/v) phosphoric acid) and after 10 min the absorption was measured at 540 nm. The nitrite concentrations were calculated from a standard curve constructed, by instead of culture medium, adding 50 μL of between 3 to 100 μM of $NaNO_2$ to the assays.

Results

The results are shown in FIG. **6**. As can be seen from the Figure, the compounds of the invention, MSO5 and MSO9, as well as α-MSH caused a strong dose dependent inhibition of the NO-production, the potencies and efficacies of MSO5 and MSO9 being similar to that of the α-MSH. This data shows that MSO5 and MSO9 share the capacity of α-MSH to inhibit inflammation. This is because NO is a key component of inflammation.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 22

<210> SEQ ID NO 1
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: polynucleotide of interest

<400> SEQUENCE: 1

gatagcaatc gcttacggta atccggcctg 30

<210> SEQ ID NO 2
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 2

gatagcaatc 10

<210> SEQ ID NO 3
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 3

atagcaatcg 10

<210> SEQ ID NO 4
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 4

-continued

tagcaatcgc 10

<210> SEQ ID NO 5
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 5

agcaatcgct 10

<210> SEQ ID NO 6
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 6

gcaatcgctt 10

<210> SEQ ID NO 7
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 7

caatcgctta 10

<210> SEQ ID NO 8
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 8

aatcgcttac 10

<210> SEQ ID NO 9
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 9

atcgcttacg 10

<210> SEQ ID NO 10
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 10

tcgcttacgg 10

<210> SEQ ID NO 11
<211> LENGTH: 10
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 11

cgcttacggt 10

<210> SEQ ID NO 12
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 12

gaatgccatt 10

<210> SEQ ID NO 13
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 13

aatgccatta 10

<210> SEQ ID NO 14
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 14

atgccattag 10

<210> SEQ ID NO 15
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 15

tgccattagg 10

<210> SEQ ID NO 16
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 16

gccattaggc 10

<210> SEQ ID NO 17
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 17

ccattaggcc 10

<210> SEQ ID NO 18
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 18

cattaggccg 10

<210> SEQ ID NO 19
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 19

attaggccgg 10

<210> SEQ ID NO 20
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 20

ttaggccgga 10

<210> SEQ ID NO 21
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 21

taggccggac 10

<210> SEQ ID NO 22
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: polynucleotide of interest

<400> SEQUENCE: 22

caggccggat taccgtaagc gattgctatc 30

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Szardenings *et al.*

Appl. No. 09/674,733
(U.S. Natl. Phase of PCT/GB99/01388)

Int'l Filing Date: May 5, 1999

For: **Melanocortin 1 Receptor Selective Compounds**

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1085.0050000/RWE/ALS

Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a)

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

In the Specification:

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

Remarks

Applicants' Agent hereby states that the change made in the sequence listing does not include new matter. Applicants' undersigned Agent has amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Aaron L. Schwartz
Agent for Applicants
Provisional Registration No. P-48,181

Date: 6/12/01

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\Schwartz\Cases\1085\005\pto\825 amendment.wpd

SEQUENCE LISTING

<110> Szardenings, Michael
Muceniece, Ruta
Mutule, Ilze
Mutulis, Felikss
Jarl, Wikberg

<120> Melanocortin 1 Receptor Selective Compounds

<130> 1085.0050000/RWE/ALS

<140> 09/674,733
<141> 1999-05-05

<150> PCT/GB99/01388
<151> 1999-05-05

<150> SE 9801571-2
<151> 1998-05-05

<160> 15

<170> PatentIn version 3.0

<210> 1
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 1

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 2

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (7)..(7)

<223> D amino acid

<400> 2

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 3

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 3

Tyr Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 4

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocoritn receptor 1

<400> 4

Tyr Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 5

<211> 14

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 5

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val Tyr
1 5 10

<210> 6

<211> 12

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 6

Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 7

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 7

Thr Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 8

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 8

Ser Thr Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 9

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 9

Ser Ser Val Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 10

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<400> 10

Ser Ser Ile Val Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 11

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<400> 11

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 12

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> D amino acid

<400> 12

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 13

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (1)..(1)

<223> N-Methyl-L-Serine

<400> 13

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 14

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (13)..(13)

<223> MeVal

<400> 14

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 15

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide with high affinity for melanocortin receptor 1

<220>

<221> MOD_RES

<222> (7)..(7)

<223> N-Methyl-D-Phenylalanine

<400> 15

Ser Ser Ile Ile Ser His Phe Arg Trp Gly Lys Pro Val
1 5 10